Economic burden of chemotherapy-related febrile neutropenia

Journal of Supportive Oncology

Volumn 5, Issue 4 SUPPL. 2, 2007, Pages 44-46

  Weycker, Derek ^a   Malin, Jennifer ^a   Glass, Andrew ^a   Oster, Gerry ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; BREAST CANCER; CANCER CHEMOTHERAPY; COHORT ANALYSIS; CONFERENCE PAPER; CONFIDENCE INTERVAL; CONTROLLED STUDY; ECONOMIC EVALUATION; FEBRILE NEUTROPENIA; FEMALE; HEALTH CARE COST; HOSPITALIZATION; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; OUTPATIENT CARE; RETROSPECTIVE STUDY; SCORING SYSTEM;

EID: 34250651265     PISSN: 15446794     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (16)

1. Belani CP, Ramalingam S, Al-Janadi A, et al. A randomized double-blind phase II study to evaluate same-day vs next-day administration of pegfilgrastim with carboplatin and docetaxel in patients with NSCLC. Presented at the 42nd Annual Meeting of the American Society of Clinical Oncology; June 2-6, 2006; Atlanta, Georgia. Abstract 7110.
2. Biron P, Ray-Coquard I, Le Cesne A, et al. ELYPSE 2: a prospective randomized trial comparing filgrastim in primary and secondary prophylaxis in patients at high risk for febrile neutropenia. Presented at the 42nd Annual Meeting of the American Society of Clinical Oncology; June 2-6, 2006; Atlanta, Georgia. Abstract 8614.
3. Chellama MK, Awadhi SA, Vyas V, et al. Prevention of febrile neutropenia by prophylactic use of G-CSF with adjuvant TAC based on risk assessment - single institute study. Presented at the 42nd Annual Meeting of the American Society of Clinical Oncology; June 2-6, 2006; Atlanta, Georgia. Abstract 10711.
4. Doyle A, Keegan K, Mullen K, Zecha G, Boyd CA, Hutson J. The role of the oncology nurse in prechemotherapy neutropenic risk assessment and patient outcomes. Presented at the 31st Annual Congress of the Oncology Nursing Society; May 4-7, 2006; Boston, Massachusetts. Abstract 119.
5. Maxwell C, Stein A. Implementation of practice guidelines for chemotherapy-induced neutropenia:from paper to practice. Presented at the 31st Annual Congress of the Oncology Nursing Society; May 4-7, 2006; Boston, Massachusetts. Abstract 120.
6. Morrison VA, Wong M, Campos LT, Ding B, Malin JL. Variations in patterns of care of colony stimulating factors: implications for the effectiveness of filgrastim and pegfilgrastim in community practice. 19th Annual Meeting & Showcase Academy of Managed Care Pharmacy; April 5-8, 2006; Seattle, Washington. Abstract 27.
7. Noga SJ, Choksi J, Ding B, Dreiling L, Ozer H. Final results of a large, community-based study evaluating the impact of first and subsequent cycle pegfilgrastim on neutropenic events in non-Hodgkin's lymphoma and Hodgkin's disease patients. Presented at the 48th Annual Meeting of the American Society of Hematology; December 9-12, 2006; Orlando, Florida. Abstract 1153.
8. Ozer H, Mirtsching B, Rader M, Ding B,Truscinski D, Dreiling L. Final results of a large, community-based, prospective study evaluating the impact of first and subsequent cycle pegfilgrastim on neutropenic events in patients receiving myelosuppressive chemotherapy. Presented at the 42nd Annual Meeting of the American Society of Clinical Oncology; June 2-6, 2006; Atlanta, Georgia. Abstract 8569.
9. Pettengell R, Skacel T, Aapro M, Duehrsen U, Easton V, Lyman G.Pegfilgrastim provides effective primary prophylaxis against febrile neutropenia in patients with NHL undergoing chemotherapy:initial results from an integrated analysis - the Neulasta Versus Current Neutropenia Management Practice (NEUCUP) Project. Presented at the 48th Annual Meeting of the American Society of Hematology; December 9-12, 2006; Orlando, Florida. Abstract 1150.
10. Pettengell R, Bosly A, Szucs TD, et al. Impact of febrile neutropenia and colony stimulating factor use on chemotherapy delivery in patients with lymphoma: results from the INC-EU prospective observational European Neutropenia Study. Presented at the 48th Annual Meeting of the American Society of Hematology; December 9-12, 2006; Orlando, Florida. Abstract 2444.
11. Rader M, Ding B, Dreiling L, et al. Final results of a large, community based, prospective study evaluating the impact of first and subsequent cycle pegfilgrastim on neutropenic events. Presented at the 29th Annual San Antonio Breast Cancer Symposium; December 14-17, 2006; San Antonio, Texas. Abstract 6082.
12. Saven A, Schwartzberg L, Kaywin P, et al. Randomized, double-blind, phase II study evaluating same-day vs next-day administration of pegfilgrastim with R-CHOP in non-Hodgkin's lymphoma patients. Presented at the 42nd Annual Meeting of the American Society of Clinical Oncology; June 2-6, 2006; Atlanta, Georgia. Abstract 7570.
13. Schlenk RF, Dohner K, Groner S, et al. Impact of pegfilgrastim on hematological reconstitution and incidence of neutropenic fever after consolidation therapy with high-dose cytarabine in acute myeloid leukemia: comparative analysis between AMLSG 07-04 and the German AML Intergroup Trial. Presented at the 48th Annual Meeting of the American Society of Hematology; December 9-12, 2006; Orlando, Florida. Abstract 2020.
14. Scott BL, Park JY, Storer B, Marr KA, Boeckh M, Deeg HJ. Impact of pretransplant neutropenia on post-transplant outcome in patients with myelodysplastic syndrome (MDS). Presented at the 48th Annual Meeting of the American Society of Hematology; December 9-12, 2006; Orlando, Florida. Abstract 599.
15. Seymour JF, Morgan S, Prince M, et al. Ancestim (SCF) and high-dose twice-daily filgrastim (G-CSF) is superior to G-CSF alone or cyclophosphamide plus G-CSF for mobilization of peripheral blood stem cells (PBSC) in patients with indolent lymphoproliferative disorders previously treated with fludarabine; results of a historically-controlled phase-II study.Presented at the 48th Annual Meeting of the American Society of Hematology; December 9-12, 2006; Orlando, Florida. Abstract 3066.
16. Weycker D, Malin J, Glass A, Oster G. Economic burden of chemotherapy-related febrile neutropenia. Presented at the 42nd Annual Meeting of the American Society of Clinical Oncology; June 2-6, 2006; Atlanta, Georgia. Abstract 6068.